| Old Articles: <Older 29401-29410 Newer> |
|---|
 |
The Motley Fool
March 31, 2008
Brian Lawler |
GPC Recaps a Tough Year Development-stage drugmaker GPC Biotech releases its year-end financial results after a 2007 in which the FDA depth-charged its lead drug.   |
The Motley Fool
March 31, 2008
Alyce Lomax |
Starbucks' Lucky Clover Starbucks' acquisition of The Coffee Equipment Co., which makes the extremely high-end Clover coffee brewers, may stir up some real competitive advantage for them. |
The Motley Fool
March 31, 2008
Bill Mann |
M.D.C.'s Demented Compensation Proposals M.D.C. Holdings managers are paid for outperformance, and paid for underperformance. |
The Motley Fool
March 31, 2008
Brian Lawler |
A Little Funding for Pharmasset Development-stage drugmaker Pharmasset may be on to something with its hepatitis C compounds. |
The Motley Fool
March 31, 2008
Brian Orelli |
No Blood-Pumping Love for Merck and Schering From the reports coming out of the American College of Cardiology meeting, it looks like the drugmakers Merck and Schering-Plough took a beating. |
The Motley Fool
March 31, 2008
Rich Duprey |
Teva's Tough Pill to Swallow Eisai wins a preliminary injunction against Teva's generic Alzheimer's treatment. |
The Motley Fool
March 31, 2008
Rick Aristotle Munarriz |
Sirius Deadlines, Serious Implications The interminably long merger approval process between XM and Sirius is about to get even longer. |
The Motley Fool
March 31, 2008
Brian Orelli |
Collateral Damage From an FDA Warning BioMimetic gets hit hard by a warning about a J&J drug. |
The Motley Fool
March 31, 2008
Morgan Housel |
This Company Is Smokin' the Market Despite its lack of a highflying growth status or a glamorous line of products, Altria has been a solid performer for years. |
The Motley Fool
March 31, 2008
Anders Bylund |
Absolut-ly French, Absolut-ly Expensive It looks like Fortune Brands may have been fortunate not to win the auction for AB Vin & Spirit. |
| <Older 29401-29410 Newer> Return to current articles. |
